Therapy News and Research

RSS

RI-MUHC researchers receive innovations grants to build technologies to address cancer challenges

"Thanks to the Innovation Fund, our donors to the MGH Foundation and the vision of the Max Pacioretty Foundation, this new specialized MRI will place the Montreal General Hospital as one of the leading level 1 trauma centres in Canada. This valuable piece of healthcare technology will also allow our world-class researchers to better understand brain injuries, which will lead to improved patient diagnosis and treatment," adds Jean-Guy Gourdeau, President and Chief Executive Officer of the Montreal General Hospital Foundation at the MUHC.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Cleveland Clinic Children's to host second annual Pediatric Innovation Summit

Cleveland Clinic Children's will host its second annual Pediatric Innovation Summit June 11 to 13, 2015, at the Global Center for Health Innovation in Cleveland. Designed to promote the professional development of physicians and healthcare providers, the event will explore the current state of pediatric care and the cutting-edge medical advancements transforming the research and treatment of childhood diseases.

1 Jun 2015

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.

1 Jun 2015

International Neuromodulation Society invites media to satellite-event news briefing before 12th World Congress

Representatives of the news media are invited to a satellite-event news briefing at 11 a.m. on June 6, 2015 before the International Neuromodulation Society 12th World Congress in Montreal.

1 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.

1 Jun 2015

Alternative rehabilitation program for women diagnosed with diastasis recti

A series of online exercises and on demand curriculum is now available for women battling a not so well-known condition called diastasis recti. Founder, Raintree Sumazin, retired ballerina, pilates and yoga instructor, and certified holistic health counselor, brought this program to life after herself recovering from 8 finger diagnosis of the condition.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations.

1 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

It's a new weapon in the arsenal of cancer fighting treatments: utilizing genetically modified viruses to invade cancer cells and destroy them from the inside.

1 Jun 2015

Vascular surgeries provide relief from two debilitating conditions

When Carol Werkman first saw Loyola University Medical Center vascular surgeon Bernadette Aulivola, MD, she was suffering from two debilitating conditions: Every time she ate, Mrs. Werkman felt terrible abdominal pain. And whenever she walked more than a few hundred feet, her legs would begin to hurt.

1 Jun 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.

1 Jun 2015

Therapy News and Research

RI-MUHC researchers receive innovations grants to build technologies to address cancer challenges

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Cleveland Clinic Children's to host second annual Pediatric Innovation Summit

Statins reduce risk of death by 67% in CABG surgery

International Neuromodulation Society invites media to satellite-event news briefing before 12th World Congress

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Alternative rehabilitation program for women diagnosed with diastasis recti

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

Vascular surgeries provide relief from two debilitating conditions

Updated data from PROCLAIM national patient registry presented at 51st ASCO

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News